ClinicalTrials.gg
RecruitingNCT04369209Updated Aug 26, 2024

A Registered Cohort Study on FSHD1

An observational study in Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), sponsored by Ning Wang, MD., PhD.. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2024-08-26.

Sponsored by Ning Wang, MD., PhD. · Observational

How we know

From the registry’s dates

  • Started Jan 2001; still recruiting 25 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Study summary

The data to be collected is intended to help healthcare providers make important medical and financial decisions concerning FSHD1, through an enhanced understanding of the prevalence, progression and natural history of FSHD1.

Read the detailed description

The China FSHD1 patient registry is a nationwide, population-based, non-interventional, observational cohort clinical study of all age groups of genetically-confirmed FSHD1 patients from families (with at least 1 affected member), collecting data retrospectively at study entry and prospectively during follow up. The data to be collected is intended to help healthcare providers make important medical and financial decisions concerning FSHD1, through an enhanced understanding of the prevalence, progression and natural history of FSHD1.

02

Conditions studied

  • Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)
03

In context

Muscular Dystrophy, Facioscapulohumeral

79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 87 across 30 observational studies indexed under Muscular Dystrophy, Facioscapulohumeral.

Browse Muscular Dystrophy, Facioscapulohumeral studies →

Lead sponsor

Ning Wang, MD., PhD. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All genetically-confirmed FSHD1 patients from families (with at least 1 affected member) in China, irrespective of age. These FSHD1 patients presented at least one contracted D4Z4 repeats with 4qA-specific FSHD1-permissive haplotype, the diagnosis of which was performed at Fujian Neuromedical Center (FNMC), the clinical genetic test hospital for FSHD1 in China to employ PFGE-based Southern blotting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects of all ages at baseline
  • Subjects, with or without symptoms, with FSHD1 genetic confirmation through PFGE-based Southern blotting
  • Unrelated healthy controls

Exclusion criteria

Exclusion Criteria:

  • Decline to participate
  • Other neuromuscular disease (such as Limb-girdle muscular dystrophy or Myotonic dystrophy)
  • Serious systemic illness (such as heart, liver, kidney disease or major mental illness)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. PFGE-based Southern blotting

    Genetic test of PFGE-based Southern blotting were performed for these clinical suspected FSHD1 patients on the basis of the family as a whole. Eligible participants were genetically confirmed patients who presented a contraction to 1-10 D4Z4 repeats with a 4qA-specific FSHD1-permissive haplotype.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 years

  2. The FSHD Clinical Score

    The FSHD Clinical Score was used to define numerically the clinical severity of facioscapulohumeral muscular dystrophy (FSHD), which was divided into six independent sections that assess the strength and the functionality of (I) facial muscles (scored from 0 to 2); (II) scapular girdle muscles (scored from 0 to 3); (III) upper limb muscles (scored from 0 to 2); (IV) distal leg muscles (scored from 0 to 2); (V) pelvic girdle muscles (scored from 0 to 5); and (VI) abdominal muscles (scored from 0 to 1).

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 years

Secondary outcomes

  1. The modified Medical Research Council (MRC) scale

    The modified Medical Research Council (MRC) scale was used to assess numerically the muscle strength of FSHD participants. Firstly, muscles were tested bilaterally (when applicable) in standardized positions with manual muscle testing (MMT) scores. Then, MMT scores were converted to calculable data of the modified MRC scale.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 years

  2. The Comprehensive Clinical Evaluation Form (CCEF)

    The 2016 Comprehensive Clinical Evaluation Form (CCEF) for FSHD was used to classify phenotypes: category A , typical penetrant patients with both facial and upper limb muscle weakness (subcategories A1: severe facial weakness; A2, moderate facial weakness; A3: only upper or lower facial weakness); category B, atypical penetrant patients (subcategories B1, muscle weakness limited to scapular girdle; B2, muscle weakness limited to facial); category C, asymtomatic (subcategories C1) or nonpennetrant (subcategories C2) patients; and category D, subjects with myopathic phenotype not consistent with FSHD canonical phenotype.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2001 (actual). Primary completion is estimated for Dec 2031, 371 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2020
First posted
Apr 30, 2020
StartActual
Jan 2001
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2031
Last update
Aug 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04369209
Lead sponsor
Ning Wang, MD., PhD.
Responsible party
Ning Wang, MD., PhD. (Professor, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
Apr 30, 2020
Start date
Jan 2001
Primary completion
Dec 2031 (estimated)
Completion
Dec 2031 (estimated)
Last update
Aug 26, 2024

Study contacts

Ning Wang
Contact
ningwang@fjmu.edu.cn
13805015340 ext. 13805015340

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion